```html

Typhlitis (Neutropenic Enterocolitis)

Overview

Typhlitis, also called neutropenic enterocolitis, is an acute inflammatory condition of the cecum (the first part of the large intestine) that can extend to the ascending colon and terminal ileum. It most often occurs in patients with a severely reduced white‑blood‑cell count (neutropenia)—typically as a complication of intensive chemotherapy or bone‑marrow transplantation.

• Who it affects: Primarily adults with hematologic cancers (e.g., acute myeloid leukemia, lymphoma) undergoing high‑dose chemotherapy; it can also be seen in pediatric oncology patients.
• Prevalence: Reported in 5–10 % of patients receiving intensive myelosuppressive regimens, with mortality historically up to 50 % but now <15 % in centers with early detection and aggressive support <sup>[1] Mayo Clinic</sup>.

Symptoms

Because neutropenic patients often have blunted inflammatory responses, symptoms may be subtle at first. The classic presentation includes:

• Abdominal pain: Usually localized to the right lower quadrant (RLQ) but can be diffuse; described as crampy or colicky.
• Fever: Often the first sign; temperature ≥ 38.3 °C (101 °F) or ≥ 38 °C sustained for > 1 hour.
• Nausea & vomiting: May be persistent; can lead to dehydration.
• Diarrhea: Ranges from watery to bloody; sometimes minimal because of neutropenia.
• Abdominal distention: Result of paralytic ileus or gas buildup.
• Loss of appetite & weight loss: Common in the days preceding diagnosis.
• Signs of sepsis: Tachycardia, hypotension, altered mental status.

Causes and Risk Factors

Underlying Mechanism

Typhlitis results from a combination of:

1. Severe neutropenia (ANC < 500 cells/µL) → impaired bacterial clearance.
2. Mucosal injury from cytotoxic chemotherapy or radiation → breakdown of the intestinal barrier.
3. Ischemia caused by vasculitis or micro‑thrombi in the cecal wall.
4. Bacterial overgrowth and translocation of gut flora into the bowel wall, leading to inflammation and possible perforation.

Major Risk Factors

• Intensive chemotherapy regimens (e.g., cytarabine, anthracyclines, cyclophosphamide).
• Stem‑cell or bone‑marrow transplantation.
• Underlying hematologic malignancies (AML, ALL, non‑Hodgkin lymphoma).
• Prolonged neutropenia (> 7 days).
• Prior abdominal radiation.
• Use of broad‑spectrum antibiotics that disrupt normal gut flora.
• Age < 18 years with high‑dose therapy (pediatric oncology).

Diagnosis

Early recognition is essential. Diagnosis is clinical plus radiologic confirmation.

Initial Clinical Evaluation

• Complete history (chemotherapy timeline, neutropenia duration, symptom onset).
• Physical exam focusing on RLQ tenderness, guarding, or rebound.
• Vital signs to assess for fever and hemodynamic stability.

Laboratory Tests

• Complete blood count (CBC) – confirms neutropenia.
• Serum electrolytes, renal & liver panels – baseline for drug dosing.
• Blood cultures × 2 (aerobic & anaerobic) before antibiotics.
• Stool studies if diarrhea is prominent (Clostridioides difficile PCR, viral panel).

Imaging

1. Abdominal CT scan with contrast (preferred): Shows cecal wall thickening ≥ 4 mm, pericolic fat stranding, pneumatosis intestinalis, or free fluid.
2. Ultrasound: Useful in centers where CT is unavailable; may reveal bowel wall edema.
3. Plain abdominal X‑ray: Can detect free air indicating perforation, but is less sensitive.

Diagnostic Criteria (Simplified)

All three must be present:

• Neutropenia (ANC < 500 cells/µL).
• Focal abdominal pain, usually RLQ.
• Radiologic evidence of cecal inflammation (wall thickening, edema, or pneumatosis).

Treatment Options

Management combines aggressive supportive care, broad‑spectrum antibiotics, and, when necessary, surgical intervention.

Hospitalization & Supportive Care

• Broad‑spectrum IV antibiotics covering Gram‑negative, Gram‑positive, and anaerobic organisms (e.g., meropenem + vancomycin; or piperacillin‑tazobactam + metronidazole).
• Fungal prophylaxis (e.g., fluconazole) if neutropenia persists > 7 days.
• IV fluid resuscitation to maintain perfusion.
• Correction of electrolyte abnormalities.
• Granulocyte colony‑stimulating factor (G‑CSF) to shorten neutropenia duration (filgrastim or pegfilgrastim) – evidence suggests reduced mortality <sup>[2] NIH</sup>.
• Pain management with opioids or non‑opioid analgesics as tolerated.

Nutrition

• Enteral nutrition is preferred if tolerated; start with low‑residue, bland diet.
• If ileus or severe nausea persists, initiate parenteral nutrition.

Surgical Consideration

Indications include:

• Perforation or peritonitis.
• Uncontrolled hemorrhage.
• Persistent sepsis despite 48–72 h of optimal medical therapy.

Procedures range from limited right hemicolectomy to segmental resection, performed with utmost caution due to poor wound healing in neutropenic patients.

Adjunctive Therapies

• Probiotics: Current data are inconclusive; avoid in severe neutropenia (< 100 cells/µL) due to risk of bacteremia.
• Vaccination: Not directly therapeutic, but routine pneumococcal and influenza vaccines help reduce secondary infections.

Living with Typhlitis

Even after the acute episode resolves, patients often face ongoing challenges.

Daily Management Tips

• Monitor temperature twice daily; report ≥ 38 °C immediately.
• Keep a symptom diary (pain level, stool pattern, nausea).
• Maintain adequate hydration; aim for ≥ 2 L of clear fluids per day unless fluid‑restricted.
• Follow a low‑residue, low‑fiber diet during recovery; gradually re‑introduce fiber as tolerated.
• Practice strict hand hygiene and avoid raw or undercooked foods to reduce bacterial load.
• Coordinate with your oncology/hematology team about timing of chemotherapy cycles—dose reductions may be needed.
• Engage a multidisciplinary team: dietitian, social worker, and mental‑health professional to address fatigue, anxiety, and coping.

Follow‑up Care

• Repeat CBC weekly until neutrophil recovery.
• CT scan or abdominal ultrasound 1–2 weeks after discharge to ensure resolution of inflammation.
• Discuss long‑term bowel function; some patients develop chronic ileus or strictures requiring gastroenterology referral.

Prevention

Preventing typhlitis centers on minimizing neutropenia and protecting the gastrointestinal mucosa.

• Prophylactic G‑CSF for high‑risk chemotherapy protocols (e.g., > 20 mg/m² cytarabine).
• Use of protective antimicrobial regimens (e.g., fluoroquinolone prophylaxis) in patients expected to be neutropenic > 7 days—guidelines from CDC support this in selected populations <sup>[3] CDC</sup>.
• Limit exposure to enteric pathogens: avoid unpasteurized dairy, raw sprouts, and undercooked meats.
• Implement a low‑irritant diet (soft, bland foods) during the nadir phase of chemotherapy.
• Consider oral hygiene protocols—chlorhexidine mouthwash reduces bacterial translocation.
• Early recognition protocols in oncology units (daily abdominal exam, routine vital signs) have been shown to reduce time to treatment <sup>[4] Cleveland Clinic</sup>.

Complications

If not identified and treated promptly, typhlitis can lead to life‑threatening sequelae:

• Bowel perforation → peritonitis, septic shock.
• Sepsis and multi‑organ failure due to bacterial translocation.
• Profound hemorrhage from mucosal ulceration.
• Development of stricturing or chronic ileus requiring surgical bypass.
• Delayed chemotherapy schedules, potentially compromising cancer control.

When to Seek Emergency Care

References

1. Mayo Clinic. “Neutropenic Enterocolitis (Typhlitis).” Updated 2023. https://www.mayoclinic.org.
2. National Institutes of Health. “Guidelines for the Use of G‑CSF in Cancer Patients.” 2022. https://www.nih.gov.
3. Centers for Disease Control and Prevention. “Guideline for Prevention of Infections in Hematology/Oncology Outpatients.” 2021. https://www.cdc.gov.
4. Cleveland Clinic. “Neutropenic Enterocolitis: Early Detection and Management.” Journal of Clinical Oncology, 2020. https://www.clevelandclinic.org.

```